These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 17107795)

  • 1. PDE5 inhibitors: An original access to novel potent arylated analogues of tadalafil.
    Beghyn T; Hounsou C; Deprez BP
    Bioorg Med Chem Lett; 2007 Feb; 17(3):789-92. PubMed ID: 17107795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues.
    Daugan A; Grondin P; Ruault C; Le Monnier de Gouville AC; Coste H; Linget JM; Kirilovsky J; Hyafil F; Labaudinière R
    J Med Chem; 2003 Oct; 46(21):4533-42. PubMed ID: 14521415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues.
    Daugan A; Grondin P; Ruault C; Le Monnier de Gouville AC; Coste H; Kirilovsky J; Hyafil F; Labaudinière R
    J Med Chem; 2003 Oct; 46(21):4525-32. PubMed ID: 14521414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.
    Blount MA; Zoraghi R; Ke H; Bessay EP; Corbin JD; Francis SH
    Mol Pharmacol; 2006 Nov; 70(5):1822-31. PubMed ID: 16926278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke.
    Zhang L; Zhang Z; Zhang RL; Cui Y; LaPointe MC; Silver B; Chopp M
    Brain Res; 2006 Nov; 1118(1):192-8. PubMed ID: 16959227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substituted pyrazolopyridopyridazines as orally bioavailable potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction.
    Yu G; Mason H; Wu X; Wang J; Chong S; Beyer B; Henwood A; Pongrac R; Seliger L; He B; Normandin D; Ferrer P; Zhang R; Adam L; Humphrey WG; Krupinski J; Macor JE
    J Med Chem; 2003 Feb; 46(4):457-60. PubMed ID: 12570368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Furoyl and benzofuroyl pyrroloquinolones as potent and selective PDE5 inhibitors for treatment of erectile dysfunction.
    Jiang W; Sui Z; Macielag MJ; Walsh SP; Fiordeliso JJ; Lanter JC; Guan J; Qiu Y; Kraft P; Bhattacharjee S; Craig E; Haynes-Johnson D; John TM; Clancy J
    J Med Chem; 2003 Jan; 46(3):441-4. PubMed ID: 12540243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors.
    Corbin JD; Beasley A; Blount MA; Francis SH
    Biochem Biophys Res Commun; 2005 Sep; 334(3):930-8. PubMed ID: 16023993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent and selective xanthine-based inhibitors of phosphodiesterase 5.
    Arnold NJ; Arnold R; Beer D; Bhalay G; Collingwood SP; Craig S; Devereux N; Dodds M; Dunstan AR; Fairhurst RA; Farr D; Fullerton JD; Glen A; Gomez S; Haberthuer S; Hatto JD; Howes C; Jones D; Keller TH; Leuenberger B; Moser HE; Muller I; Naef R; Nicklin PA; Sandham DA; Turner KL; Tweed MF; Watson SJ; Zurini M
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2376-9. PubMed ID: 17337182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrroloquinolone PDE5 inhibitors with improved pharmaceutical profiles for clinical studies on erectile dysfunction.
    Jiang W; Guan J; Macielag MJ; Zhang S; Qiu Y; Kraft P; Bhattacharjee S; John TM; Haynes-Johnson D; Lundeen S; Sui Z
    J Med Chem; 2005 Mar; 48(6):2126-33. PubMed ID: 15771456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of different heterocyclic scaffolds as substrate analog PDE5 inhibitors.
    Haning H; Niewöhner U; Schenke T; Lampe T; Hillisch A; Bischoff E
    Bioorg Med Chem Lett; 2005 Sep; 15(17):3900-7. PubMed ID: 15993055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3D-QSAR studies on sildenafil analogues, selective phosphodiesterase 5 inhibitors.
    Yoo J; Thai KM; Kim DK; Lee JY; Park HJ
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4271-4. PubMed ID: 17553682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JNJ-10280205 and JNJ-10287069: Novel PDE5 inhibitors as clinical candidates for erectile dysfunction.
    Qiu Y; Bhattacharjee S; Kraft P; Mathew John T; Haynes-Johnson D; Jiang W; Sui Z; Lundeen S
    Int J Impot Res; 2006; 18(5):477-83. PubMed ID: 16528290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyrimidinylpyrroloquinolones as highly potent and selective PDE5 inhibitors for treatment of erectile dysfunction.
    Sui Z; Guan J; Macielag MJ; Jiang W; Zhang S; Qiu Y; Kraft P; Bhattacharjee S; John TM; Haynes-Johnson D; Clancy J
    J Med Chem; 2002 Sep; 45(19):4094-6. PubMed ID: 12213052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular modeling studies of pyridopurinone derivatives--potential phosphodiesterase 5 inhibitors.
    Srivani P; Srinivas E; Raghu R; Sastry GN
    J Mol Graph Model; 2007 Jul; 26(1):378-90. PubMed ID: 17307372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and cyclic GMP phosphodiesterase inhibitory activity of a series of 6-phenylpyrazolo[3,4-d]pyrimidones.
    Dumaître B; Dodic N
    J Med Chem; 1996 Apr; 39(8):1635-44. PubMed ID: 8648603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PDE5 inhibition and fibrosis.
    Corbin J
    Int J Impot Res; 2005; 17(6):546. PubMed ID: 16258527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roundtable discussion: tadalafil study group.
    Kloner RA; Brindis RG; Cheitlin MD; Kuritzky L; Miller TA; Padma-Nathan H; Rosen RC
    Am J Cardiol; 2003 Nov; 92(9A):58M-65M. PubMed ID: 14609624
    [No Abstract]   [Full Text] [Related]  

  • 19. A chemometric study of phosphodiesterase 5 inhibitors.
    de O Figueiredo LJ; Garrido FM; Kunisawa VY; Aboim CE; Licks OB
    J Mol Graph Model; 2006 Jan; 24(4):227-32. PubMed ID: 16185904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel pyrazolopyrimidopyridazinones with potent and selective phosphodiesterase 5 (PDE5) inhibitory activity as potential agents for treatment of erectile dysfunction.
    Giovannoni MP; Vergelli C; Biancalani C; Cesari N; Graziano A; Biagini P; Gracia J; Gavaldà A; Dal Piaz V
    J Med Chem; 2006 Aug; 49(17):5363-71. PubMed ID: 16913726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.